|
See related Klacid information |
|
|
|
Manufacturer |
Abbott |
|
Distributor |
Zuellig |
|
Contents |
Clarithromycin |
|
Indications |
Lower & upper resp tract, soft tissue, skin & skin structure infections. Prevention & treatment of Mycobacterium avium complex (MAC) infection. H. pylori infection. Acute otitis media. Odontogenic infection.
Click to view Klacid detailed prescribing infomation |
|
Dosage |
Klacid tab 250 mg bid. Severe infections 500 mg bid. MAC infection 500-1,000 mg bid. H. pylori infection 500 mg bid. Klacid ped susp 7.5 mg/kg bid. Klacid vial 500 mg bid 2-5 days. Klacid MR tab 500 mg once daily. May be increased to 1,000 mg once daily. Duration: 6-14 days.
Click to view Klacid detailed prescribing infomation |
|
Overdosage |
View Klacid overdosage for action to be taken in the event of an overdose. |
|
Administration |
MR tab:Should be taken with food (Swallow whole, do not chew/crush.); Tab/Susp:May be taken with or without food. |
|
Contraindications |
Known hypersensitivity to macrolides. Patients receiving terfenadine, pimozide or cisapride.
Click to view Klacid detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Klacid detailed prescribing infomation |
|
Special Precautions |
Impaired hepatic function & moderate to severe renal impairment.
Click to view Klacid detailed prescribing infomation |
|
Adverse Drug Reactions |
Nausea, dyspepsia, abdominal pain & diarrhea. Headache & skin rash. Alteration of sense of smell w/ taste perversion.
View ADR Monitoring Form |
|
Side Effects |
View Klacid side effects |
|
Drug Interactions |
Theophylline, carbamazepine, warfarin, digoxin, terfenadine & ritonavir.
View more drug interactions with Klacid |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Klacid storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Klacid description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Klacid mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
